|
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy |
May 2024 |
International Journal of Laboratory Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome |
May 2024 |
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
|
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) |
May 2024 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
May 2024 |
Pediatric Blood & Cancer |
Aplastic Anemia |
|
Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials |
May 2024 |
Current Medical Research and Opinion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes |
May 2024 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
May 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
Apr 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia |
Apr 2024 |
Blood Advances |
Aplastic Anemia |
|
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
Apr 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
